Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | BHVN | Common Shares | Other | $0 | +2.54K | $0.00 | 2.54K | Oct 3, 2022 | Direct | F1, F2 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | BHVN | Stock Options (Right to Buy) | Award | $0 | +125K | $0.00 | 125K | Oct 3, 2022 | Common Shares | 125K | $7.00 | Direct | F3 |
Id | Content |
---|---|
F1 | Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding restricted share unit of RemainCo was adjusted so that such restricted share unit became a restricted share unit in respect of common shares ("Common Shares") of the Issuer (each, an "Issuer RSU") and a restricted share unit in respect of RemainCo common shares. (Cont'd in FN2) |
F2 | (Cont'd from FN1) As a result, the Reporting Person acquired restricted share units in respect of Common Shares in an amount determined in accordance with the Separation Agreement. At the effective time of the merger of a wholly owned subsidiary of Pfizer ("Merger Sub") with and into RemainCo pursuant to the Agreement and Plan of Merger, dated as of May 9, 2022, by and among RemainCo, Pfizer and Merger Sub, the Issuer RSUs accelerated and vested in full and will subsequently be settled in Common Shares. |
F3 | The shares underlying this option vest in four equal installments on October 3, 2022, 2023, 2024, and 2025, subject to the Reporting Person's continuous service with the Issuer at each vesting date. |